April 29, 2022

From Eric's Desk

I have never been a fan of Hallmark holidays. I worry about the proliferation of days, weeks, and months that are designated for individuals or causes. Maybe this is just one of my many personality flaws and related to my irreverent nature. The causes are almost always worthy, and it is good to recognize others. But be sure that I will go into hiding if there is ever a “Cancer Center Director’s Day.”

HOWEVER, I make a major exception for National Nurses Week, which begins next week. My only complaint is that Nurses Week should be every week of the year. And of all nurses, oncology nurses are particularly near to my heart. Whether we are talking about infusion nurses, practice nurses, research nurses, inpatient nurses, nurse practitioners or others, these individuals deserve our endless respect, gratitude, and admiration. Oncology nurses are an absolutely critical component of any Cancer Center, and our patients both appreciate them and know that nurses hold the key to all solutions. As cancer care has evolved, oncology nursing has become even more important. The oncology nurse serves as both an indispensable provider of care, and the link to the physician staff, the social workers, the pharmacists, and so many more.

As a clinician, I am often asked to describe the team of providers who are involved in a patient’s care. I describe all of the physicians, and never fail to talk about the nurses and how essential they are to achieving the best care and outcomes for a patient. Before coming to Yale, I had the pleasure of working with the same nurse practitioner for 15 years. When describing Jen to patients, I always told them that if I had breast cancer, Jen is the medical professional I would turn to for care and to help guide me through the entire process.

Thanks to each one of our hundreds of Smilow nurses for all they do for our patients, for their colleagues, and for Yale every day of the year. Happy National Nurses Week!

Eric

Announcements

Hematology Hires two Fellows to Faculty Positions
Hematology Hires two Fellows to Faculty Positions

Yale Cancer Center is pleased to welcome Anna Kress, MD, and George Goshua, MD, MSc, to the section of Hematology. Drs. Kress and Goshua will both complete the Yale Medical Oncology-Hematology Fellowship Program and begin their new appointments in July. Dr. Kress will care for patients as part of the Smilow Classic Hematology Program at the Smilow Cancer Hospital Care Centers in North Haven and in Trumbull. Dr. Goshua will both see patients as part of the Smilow Classic Hematology Program and build the first research program in the country that is focused on decision-analytic modeling and health economics in classical hematology.

Dr. Kress received her medical degree from Columbia University where she also completed her residency. She will be an Assistant Professor of Medicine (Hematology). During her time as a Chief Fellow at Yale, Dr. Kress was instrumental in creating Yale’s first Diversity, Equity, and Inclusion curriculum as part of the Yale Medical Oncology-Hematology Fellowship Program. This initiative continues to facilitate broader discussions on disparities in medicine.

Dr. Goshua received his medical degree from the University of Kentucky College of Medicine and completed his residency at Yale New Haven Hospital, serving as Chief Resident and Instructor of Medicine in 2018-2019. During his fellowship at Yale, he received a Master of Science degree in Risk and Decision Sciences from the Harvard T.H. Chan School of Public Health and built a Yale-led multi-institutional, collaborative research hub that includes the University of Pennsylvania, Harvard Medical School, Boston University, University of California-San Francisco, and the University of British Columbia. He will be an Assistant Professor of Medicine (Hematology). Dr. Goshua has authored seven original science, first-author publications in Blood, The Lancet Haematology, The Lancet Regional Health, Blood Advances, and the American Journal of Hematology. In addition to the recognition his work has received from the American Society of Hematology, European Hematology Association, and the Hemostasis and Thrombosis Research Society, he is the 2021-22 Yale Bernard G. Forget Scholar and the 2021 American Journal of Hematology Young Investigator Award recipient.

ASCO Reception

Ansley Roche, MD, in honor of Head and Neck Cancer Awareness Month

Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer

The Cancer Care Crisis in Ukraine

How You Can Help
Yale Cancer Center and Smilow Cancer Hospital will host a Dessert Reception at the ASCO Annual Meeting on Sunday, June 5 at 8:30pm at 720 South Bar, Hilton Chicago. All are welcome to attend.

Learn more

Notables

Cary Gross, MD, Professor of Medicine and Epidemiology and Director of the Center for Cancer Outcomes, Public Policy, and Effectiveness Research, has been named to the Association of American Physicians (AAP). Election to the AAP is an honor extended to physicians with outstanding credentials in basic or translational biomedical research and is limited to 70 persons per year.

David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology), has been named a Goodman and Gilman Yale Scholar, an award that recognizes junior faculty members at Yale School of Medicine for their research and research potential. Dr. Braun has a longstanding interest in integrating experimental and computational approaches to biomedical research and is currently studying mechanisms of response and resistance to immune therapy in kidney cancer, with the goal of developing novel therapies.

Aileen Fernandez, PhD, postdoctoral fellow in the laboratory of David Rimm, MD, PhD, and Krishna Mudumbi, PhD, postdoctoral associate in the laboratory of Mark Lemmon, PhD, FRS, have been selected as Duke Next Generation Leaders, a new initiative at Duke University aimed at bringing together cohorts of talented postdoctoral scientists and mentoring them for academic faculty careers. They were among six people selected for their research interests and their embodiment of the ideal of increasing diversity in the sciences. They will present their work during a multi-day visit to Duke in May. Dr. Fernandez is co-chair of the Yale Black Postdoctoral Association, of which Dr. Mudumbi is vice chair. Dr. Mudumbi is also co-chair of the Yale Postdoctoral Association.

Ruslan Medzhitov, PhD, Sterling Professor of Immunobiology and an investigator at the Howard Hughes Medical Institute, has been elected to the Read More

Greenwich Hospital asked 200 residents about creating a cancer care facility. Here’s how they felt.

How to Tell whether a Cancer Is Caused by Plain Bad Luck

Follow us!
Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology), has been reappointed as a Komen Scholar for a 3-year term to help lead the Susan G. Komen scientific peer review process.

The Federation of American Societies for Experimental Biology (FASEB) has honored Valentina Greco, PhD, Carolyn Walch Slayman Professor of Genetics and Professor of Cell Biology and Dermatology, with its Mid-Career Investigator Award.

Sayeef Mirza, MD, MPH, Clinical Fellow in the Medical Oncology-Hematology Fellowship Program, has been accepted to participate in the prestigious 2022 American Society for Transplantation and Cellular Therapy (ASTCT) Clinical Research Training Course in Park City, Utah this summer.

Xinyan Zhang, MD, PhD, postdoctoral associate in the laboratory of Xiaolei Su, PhD, Jianshu Wang, PhD, postdoctoral associate in the laboratory of David Schatz, PhD, and Ashish Kumar, PhD, postdoctoral associate in the laboratory of Franziska Bleichert, PhD, received Leslie H. Warner Postdoctoral Fellowships from Yale Cancer Center. The Fellowships support early-stage promising trainees that are conducting innovative basic, translational, clinical, or population-based cancer research with a Yale Cancer Center member.

The Healio publications company is launching Healio Disruptive Innovators Awards and soliciting votes for this year’s awardees, including Yale Cancer Center’s Barbara Burtness, MD, Pamela Kunz, MD, and Tara Sanft, MD, each nominated for awards. Please take a moment to vote and support your colleagues! The awards will be presented on Saturday, June 4th, during the ASCO Annual Meeting at the Hyatt Regency McCormick Place.

This year’s Oncology Nursing Society Congress in Anaheim, California will have wonderful representation from our oncology nursing team from Smilow Cancer Hospital and Yale Cancer Center thanks to the dedicated efforts of our nurses and many mentors throughout our health system. The following abstracts have been accepted for presentation at this year’s Congress.

*The Ambulatory Oncology Clinic Visit: Establishing Workflows to Ensure Patient Visit Readiness*
Mandeep Smith, APSM, Christina Matousek, Connie Engelking, Monica Fradkin, RN, MPH

*Ambulatory Acuity Tool: Taking it up a Notch*
Brooke Schrameck, Krista Bello, RN, OCN Roberta Sterling, MSN, MPH, RN, CNML, Mandeep Smith, APSM & Sandy Morgan, RN

*Making the Case for Remote Work for Oncology Nursing during Transitional Times*
Camille Servodidio, RN, BSN, MPH Gean Brown, MSN, RN, Shagunna Muse, MBA, Kylie Kuck, MSN, AGNS-BC, CCTN, Donna Viner, RN, Xiaohan Zhou

*Innovations in the Elective Chemotherapy Admission Process*

Meet Andrea Silber, MD, medical oncologist at Smilow Cancer Hospital. Dr. Silber cares for women with breast cancer. Recently, a patient of Dr. Silber’s shared:

"Dr. Silber, my oncologist, is the best. She has my total trust and I believe she saved my life. She is very professional and straightforward in the way she explains matters. Her Nurse Assistant, Carol, is very efficient and follows through on every detail."
Innovations in the Elective Chemotherapy Admission Process
Nicole Bocchetta, Brianna Lutz, Eileen Dehm, RN, BSN

Maintaining Patient Care in the Age of Cyber Attacks
Cara Henderson, RN, Kelli-Ann Mancini

Designing Ambulatory Workflow with Scheduling Trigger to Improve RN Utilization of a Dedicated Pre-Treatment Patient Education Visit via Telehealth
C Sumpio, PhD, MSN, RN, AOCNS, Elizabeth Rosenberg, DNP, MA, RN, OCN, CNML, Paula Pike, RN, BSN Mandee Smith, APSM, Nicole Bocchetta, Donna LaPolt, PCA

High dose trifluraste in the ambulatory setting
Kelli-Ann Mancini, Catherine Sumpio, PhD, MSN, RN, AOCNS, Kirsten Pedersen, MSN, RN

Hyperthermic Intraperitoneal Chemotherapy: Implementation & Education for the Non-Oncology Healthcare Worker
Christina Matousek, Eva Nicola Rosselli, RN, MSN, Amanda Luckyx, Dana Clifton, Carolina Pires-Dionisio, Lisa Barbarotta, MSN, APRN

Administering Subcutaneous (SubQ) Hyaluronidase Injections with a Medication Extension Set (ExSet)
Sarah DiGirolamo, Elizabeth Gineo, RN, Eva Nicola Rosselli, RN, MSN, Nicole Bocchetta, Cathy Sumpio, PhD, MSN, RN, AOCNS

Standardizing education for implanted venous port nurse champions across a healthcare system
Eva Nicola Rosselli, RN, MSN Kylie Kuck, MSN, Patti Szabo

An innovative approach to Continuing Education and Professional Development
G Brown, MSN, RN, N Bocchetta, E Gineo, RN, C Matousek, P Szabo

The Commission on Cancer 4.2 Standard: An Innovative Approach to Ensure Compliance (tracking)
D’Ana Brooks, E. Gineo, RN, C. Matousek, K. Mancini

Responding to medical emergencies in an ambulatory oncology setting
Patti Szabo

Nurse Coordinators Teams up with Nurse Analyst to Create Electronic Intake Questionnaire for Breast Center Patients
Sherri Storms, MSN, RN, Sandra Hurd, MPH, BSN, RN

Improving Nurse Responsiveness on Inpatient Oncology Units
Brianna Lutz, Laurie Crouch, Desiree Sanches

Using the Covid-19 Pandemic to Launch Ambulatory Cancer Care Delivery Workflow Transformation
Monica Fradkin, RN, MPH, Anne Chiang, MD, PhD, Jeremy Kortmansky, MD

Racial Diversity Within Oncology Healthcare Leadership Increases Positive Outcomes
Alienne Salleroli, MSN, BSN, RN, OCN

Cancer research is full of databases that capture widely different aspects of the disease, from tumor samples and genomic sequencing to clinical study results, sociodemographics, and billing. This information gets warehoused in unconnected data sets, investigated by different types of researchers, and published in journals specific to their focus of research.

New research from Yale Cancer Center led by Michaela Dinan, PhD, demonstrates that when disparate data sets are pushed into conversation with each other, they can disclose new insights about cancer, cancer care, and the healthcare system.

If anyone has ever been predisposed to seek out healthcare as a calling, it’s Javin Brita, PA-C, MPAS. Growing up in a small town in rural Massachusetts he heard stories of how his great grandmother supported the local community by working as a midwife. Deeply inspired by his family's history of service, Javin resolved from a young age to find a profession that would allow him to provide care for people in need of expert
Diversity, Equity, and Inclusion

Grand Rounds on Tuesday, May 3
Please join us for Grand Rounds on Tuesday presented by Reshma Jagsi, MD, DPhil, Newman Family Professor and Deputy Chair in the Department of Radiation Oncology and Director of the Center for Bioethics and Social Sciences in Medicine at the University of Michigan. Dr. Jagsi will present on “Promoting Equity for Women in Oncology: An Evidence-Based Approach.”
Learn more

Gender Pay Gap Affects Most Medical Specialties, Persists Over Time
Women earn less than men in more than 90% of academic medical specialties, both when starting their careers and 10 years later, according to a study published in JAMA Network Open.

The data suggest that the average starting salary for women in academic medicine is 10% lower than the average starting salary for men. After a decade on the job, the average salary for women is 9% lower. Differences of this magnitude can equate to a million dollar or greater difference in lifetime earning potential.

“Over the last few years, we’ve increasingly seen more objective data around all types of gender disparities in medicine, and this new paper contributes to that,” said Pamela Kunz, MD, Associate Professor of Medicine (Medical Oncology), and Vice Chief of DEI for Medical Oncology.

“Objective data is helpful, but I think that many of us in this space are starting to ask, how much more data do we need? There’s clearly a problem, and I think we need to really pivot towards focusing on the solutions,” said Dr. Kunz.
Read more in Cancer Therapy Advisor

Yale Cancer Center Trainee Colloquium

Yale Cancer Center will hold its Fifth Annual Trainee Colloquium virtually on Friday, June 10, 2022 from 8:30am - 1:15pm. This will be a forum for Yale trainees to highlight their research, exchange ideas, and initiate collaborations. We invite predoctoral MD, PhD, MD-PhD students, postdoctoral associates, postdoctoral fellows, residents, and clinical fellows engaging in cancer research to submit abstracts describing their work.

The colloquium will include presentations from trainees in the following four areas: 1) Basic Science Research and Bioinformatics, 2) Translational Research, 3) Clinical Research, 4) Population Science, Prevention and Outcomes Research. The Yale Cancer Center Education Committee will review all abstracts and make selections for oral presentations. Each presentation will be 10 minutes, and presenters will be notified by May 30, 2022. Four Research Excellence Prize recipients will be selected from among the oral presentations. Winners will be announced during the colloquium and each awardee will receive an award certificate and an award of $250.

Read More

Meet Christin Knowlton, MD, MA, radiation oncologist and medical director of our Smilow Cancer Hospital Care Center in Hamden. Recently, a patient of Dr. Knowlton’s shared:

“Dr. Knowlton is a wonderful provider. Very knowledgeable, explains things completely and makes sure you understand. She is also very compassionate.”
We understand that your research progress may have been delayed due to the COVID-19 shutdown, and we encourage you to submit the data that you have. We will consider this important factor when we judge your work.

Eligibility:
- Current Yale MD, PhD, and MD-PhD students
- Current Yale postdoctoral associates, postdoctoral fellows, residents, and clinical fellows
- Abstract submission must be approved by the mentor

Submission Guidelines:
- Abstracts should be 300 words or less, and may include one figure
- The deadline for abstract submission is **May 20, 2022, at 5pm EST**

Online Registration and Abstract Submission
Questions, please contact **Meina Wang**.

---

**Employee Profile: Victoria Taiwo**

Victoria (Vickey) Taiwo, MHA, Program Coordinator at Smilow Cancer Hospital, works closely with both Kerin Adelson, MD, Chief Quality Officer, and Michele Kelvey-Albert, MPH, Director of Quality and Patient Safety, to make sure that our patients are receiving the highest standard of care. In this role, she serves as a liaison between clinical program leaders and leadership teams, while developing and implementing new programmatic initiatives. Vickey tracks a project’s progression and generates metrics to evaluate program quality and compliance.

Vickey was instrumental in helping to launch the Hospitalist Program at Smilow. She tracked key action items and helped to create the final document that outlined the program and the associated roles and responsibilities. She is currently managing the certification process for Smilow to be considered an oncology medical home through ASCO. This national certification acknowledges that quality patient care is being provided, efforts are being made to reduce costs, and care is being standardized across care locations.

Although Vickey is not providing direct patient care, what she does impacts patients directly in the clinic and the care they receive. Her current supervisor, Nara Sinanis, MPH, CHES, Oncology Care Model Program Manager, will soon begin a new role with the Office of Strategy Management, and Vickey will be the Interim Program Manager during the transition. Nara commented, “Vickey is an exceptional coordinator who uses her project management expertise to structure project work, track deliverables, and keep open communication with staff. She’s a highly collaborative and supportive team member who maintains a positive outlook and has been instrumental in...”

---

Read More

John Gerrity, a speech pathologist at Smilow Cancer Hospital works with our patients to improve quality of life. “A speech pathologist provides education on how speech, voice, and swallowing may be impacted by treatment.”

---

Read More

Leah Tenenbaum, the Smilow Cancer Hospital Palliative Care Program Inpatient Chaplain, has recently achieved certification as a Palliative Care and Hospice Advanced Certified Chaplain by the Board of Chaplaincy Certification (BCCI). This advanced certification is a first for the Department of Spiritual Care at YNHH. Nationally, there are only 54 chaplains who have reached this level of advanced certification! Congratulations, Chaplain Leah!
member who maintains a positive outlook and has been instrumental in ensuring complex initiatives run smoothly. Her contributions have been invaluable to our team and will undoubtedly improve patient-centered care delivery.

Recent Publications


**Pembrolizumab Alone Or With Chemotherapy For Recurrent Or Metastatic Head And Neck Asparagine Metabolism in Tumors is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study**

*Metabolites, 12*(2):164.

**Read More**

Woodard GA, Cho C, Chen L.

**Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?**


**Read More**

Kerekes DM, Khan SA.

**Lipid Metabolism in Biliary Tract Cancer: A New Therapeutic Target?**


**Read More**

Guise TA, Wysolmerski JJ.

**Cancer-Associated Hypercalcemia**

*NE Journal of Medicine, 386*(15):1443-1451.

**Read More**

Xiao R, Ross JS, Gross CP, Dusetzina SB, McWilliams JM, Sethi RKV, Rathi VK.

**Hospital-administered Cancer Therapy Prices for Patients with Private Health Insurance**

*JAMA Internal Medicine, Online ahead of print.*

**Read More**


**Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline**

*Journal of Clinical Oncology, 40*(12):1356-1384.

**Read More**


**Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-stage Breast Cancer: ASCO Guideline Update**

*Journal of Clinical Oncology, Online ahead of print.*

**Read More**


**Watch this week’s @YaleCancer Grand Rounds with Dr. Luisa Escobar-Hoyos @Escobar_Lab on potential #personalizedmedicine in #pancreaticcancer and Dr. Rosa Munoz Xicola on understanding sporadic and hereditary #colorectal tumors**

**Congratulations to DrRoyHerbstYale who has been named Chair of the @AACR Scientific Policy and Government Affairs Committee!**

**Please join us on 5/4 at 6PM for an overview of #cancerscreening including for #breastcancer, #cervicalcancer, and #lungcancer with @YaleCancer @SmilowCancer physicians. #bcsmlcsm #gyncsm Register now**

**Join us at Noon today for Grand Rounds. Dr. Luisa Escobar-Hoyos @Escobar_Lab will discuss altered #RNA in #pancreaticcancer and Dr. Rosa Munoz Xicola will share updates on #colorectal tumors with Mismatch Repair Deficiency.**

"The use of #freeflaps after treatment has significantly improved quality of life and allows us to remove tumors that in the past may have been considered unresectable." - Dr. Ansley Roche
Improved Survival with Enzalutamide in Patients with Metastatic Hormone-sensitive Prostate Cancer
Journal of Clinical Oncology, Online ahead of print.
Read More

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival after Neoadjuvant Chemotherapy with or without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
Journal of Clinical Oncology, 40(12):1323-1334.
Read More

ZNF117 Regulates Glioblastoma Stem Cell Differentiation towards Oligodendroglial lineage
Read More

COAST trial results in JCO_ASCO by @DrRoyHerbstYale & colleagues are the first to demonstrate improved outcomes with combinations of #immunotherapy for patients with stage III #Cancer
Read More

Dr. Pat LoRusso speaking with @ASCOPost on the 40th Anniversary of the discovery of the #RASoncogene, present in roughly 25% of all cancers, and clinical successes and challenges in targeting
Read More

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, Online ahead of print.
Read More

HMCES Protects Immunoglobulin Genes Specifically from Deletions during Somatic Hypermutation
Genes & Development, Online ahead of print.
Read More

HMCES Protects Immunoglobulin Genes Specifically from Deletions during Somatic Hypermutation
Genes & Development, Online ahead of print.

Phosphatidylerosine Synthase PTDDS1 Shapes the Tumor Lipidome to Maintain Tumor-Promoting Inflammation
Read More

**Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis**

*European Urology,* Online ahead of print.


**PTHrP Induces STAT5 Activation, Secretory Differentiation and Accelerates Mammary Tumor Development**


Rodwin RL, Ma X, Ness KK, Kadan-Lottick NS, Wang R.

**Physical Therapy Utilization among Hospitalized Patients with Pediatric Acute Lymphoblastic Leukemia**

*JCO Oncology Practice,* Online ahead of print.


**TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor**

*Molecular Cancer Therapeutics,* Online ahead of print.


**Radiotherapy Combined with Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial**

*Neuro-Oncology,* Online ahead of print.


**Hematology/Oncology Fellowship Programs’ Participation in the Quality Oncology Practice Initiative**

*JCO Oncology Practice,* Online ahead of print.
Funding and Award Opportunities

Yale SPORE in Lung Cancer Career Enhancement Program (CEP)
The CEP of the Yale SPORE in Lung Cancer has been established to educate the next generation of investigators committed to translational research in lung cancer. The CEP will provide support of up to $50,000 to promising junior investigators and/or establish investigators who have not previously conducted lung cancer focused research.
If you are interested in applying for a Full Application, please email Anna Arnal.

Yale SPORE in Lung Cancer Developmental Research Program (DRP) Award
The DRP of the Yale SPORE in Lung Cancer provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full Yale SPORE in Lung Cancer project. The purpose is also to generate preliminary data or evidence of collaboration for new NCI grant applications.
If you are interested in applying for a Full Application, please email Anna Arnal.

Yale Center for Gastrointestinal Cancers (CGIC) Seed Grant Program
This intramural seed grant program is designed to provide pilot funding for team-based basic, translational, clinical, or population health research projects focused on GI cancers.
Application Deadline: May 1, 2022
Read More
Emergency Awards: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01)
The goal of this RADx®-UP FOA is to conduct social, ethical, and behavioral implications (SEBI) research to understand and reduce barriers to COVID-19 testing, as well as COVID-19 disparities that arise from barriers to testing among underserved and vulnerable populations. The funding for this initiative is provided from the American Rescue Plan Act of 2021, PL 117-2. 
**Application Deadline:** May 2, 2022
Read More

Emergency Award: RADx-UP Community-Engaged Research on Rapid SARS-CoV-2 Testing among Underserved and Vulnerable Populations (U01)
The goals of this FOA are to implement and rigorously evaluate SARS-CoV-2 rapid testing strategies in communities experiencing COVID-19 health disparities. These two-year Rapid Testing Research Projects will evaluate (1) rapid testing interventions to prevent and control COVID-19 transmission among underserved and vulnerable populations and (2) partnership-driven research to implement and evaluate rapid testing and reduce COVID-19 disparities. The funding for this program is provided from the American Rescue Plan Act of 2021, PL 117-2.  
**Application Deadline:** May 2, 2022
Read More

Hyundai Hope On Wheels Grants
Hyundai Hope On Wheels creates awareness for pediatric cancers and awards large grants to doctors and premiere research centers for life-saving research.
- The Scholar Hope Grant: presented to researchers involved with translational research, working directly with patients.
- The Hyundai Young Investigator's Grant: provides funding for principal investigators whose research projects are likely to have a significant impact on improving the understanding of the biology of childhood cancer.

**Application Deadlines** May 6, 2022
Read More

ALSF Grant Opportunities
- **NEW! R Accelerated Grant:** This grant provides funding to scientists within their first 10 years of faculty appointment who are focused on research in pediatric oncology that support ALSF’s mission to find cures and better treatments for childhood cancers. **Deadline for Submission:** May 12, 2022
- **‘A’ Award Grant:** ALSF seeks game-changing proposals to substantially advance childhood cancer treatments and cures. The 'A' Award is designed for the early independent career scientist who wants to establish a career in pediatric oncology research and does not have NIH funding. **Deadline for Submission:** May 12, 2022
Read More

Pew-Stewart Scholars for Cancer Research
The Pew-Stewart Scholars for Cancer Research supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer. The award provides $300,000 in flexible support—$75,000 per year for a four-year period.  
**Institutional Nomination Due:** May 18, 2022
Yale Head and Neck SPORE (YHN-SPORE) Developmental Research Program (DRP)
The Yale Head and Neck SPORE’s DRP provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full YHN-SPORE project or to generate preliminary data or evidence of collaboration for other new NIH grant applications.
**Full application Due:** May 20, 2022

Yale Head and Neck SPORE (YHN-SPORE) Career Enhancement Program (CEP)
The CEP of the Yale Head and Neck SPORE has been established to educate the next generation of investigators committed to translational research in head and neck cancer. The CEP will provide support to promising junior investigators and/or established investigators who have not previously conducted head and neck cancer focused research.
**Full Application Due:** May 20, 2022

TheoryLab Collaborative Grants
The ACS is accepting Idea Abstracts through May 20 for TheoryLab Collaborative (TLC) Grants, which provide pilot grant support for innovative, collaborative research projects utilizing the ACS TheoryLab platform. Contact: Research.Integration@cancer.org with questions.
**Abstract Deadline:** May 20, 2022

AACR Clinical Oncology Research Fellows Grants
The AACR Clinical Oncology Research (CORE) Training Fellowships Program is designed to provide an effective industry-academic clinical practicum with a unique training opportunity to develop academic clinicians in drug development.
- AACR Clinical Oncology Research (CORE) Training Fellowships
- AACR-AstraZeneca Clinical Immuno- oncology Research Training Fellowships
- AACR-Bayer Clinical Oncology Research Training Fellowships
- AACR-Johnson & Johnson Lung Cancer Initiative Clinical Oncology Research Training Fellowship
**Application Deadline:** May 31, 2022

FY22 Kidney Cancer Research Program (KCRP)
The FY22 Defense Appropriations Act is anticipated to provide funding for the KCRP to support research of exceptional scientific merit in kidney cancer.
- Concept Award - Letter of Intent Due: June 23, 2022
- Idea Development Award - Preproposal Due: June 2, 2022
- Postdoctoral and Clinical Fellowship Award - Letter of Intent Due: June 23, 2022
- Translational Research Partnership Award - Preproposal Due: June 2, 2022

Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01, R21)
May 11; 12:00 PM
Makeda J. Williams, MD, MPH

Immune Development Interest Group Seminar Series
May 11; 4:00 PM
Sallie Permar, MD, MPH

Neuroendocrine Conference
May 11; 4:00 PM
*Delayed & Precocious Puberty*
Lexi Dias

2021-2022 Immunobiology Seminar Series
May 12; 10:30 AM
*Extreme Metabolism: Measuring Metabolic Flux in Immune Cells and Tumors In Vivo*
Caroline Bartman, PhD

CPC Research Program Seminar
May 12; 12:00 PM
*Racial Disparities in the Quality of Diagnostic Evaluation for Uterine Cancer*
Xiao Xu, PhD, MA

Pathology Grand Rounds
May 12; 12:30 PM

Cancer Genetics and Prevention Seminar
May 12; 2:30 PM
*National Comprehensive Cancer Network Guidelines for Genetic/Familial High Risk, Colorectal: Challenges and Opportunities*
Samir Gupta, MD, MSCS, AGAF

Center for GI Cancers Weekly Seminar/Journal Club
May 12; 4:15 PM
Xuchen Zhang, MD, PhD and Benjamin Mazer, MD, MBA

Share your news!
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
The purpose of this FOA is to solicit R01 and R21 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.

**Application Deadline:** June 5, 2022

**Read More**

**Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 and R21)**

The purpose of these FOAs is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

**Application Deadline:** June 16, 2022

**Read More**

**Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01)**

This FOA supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.

**Application Deadline:** June 17, 2022

**Read More**

**Lasker Clinical Research Scholars Program (Si2/R00)**

This program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.

**Application Deadline:** June 24, 2022

**Read More**

**Paul Calabresi Career Development Award for Clinical Oncology (K12)**

The purpose of this award is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This FOA allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

**Application Deadline:** June 25, 2022

**Read More**

**Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)**

Director, Public Affairs and Communications
Engineered Technologies for Cancer Research (R01)
This FOA will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.
Application Deadline: July 5, 2022
Read More

Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01/R21)
This FOA solicits grant applications proposing to utilize bacteria, archaeabacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics.
Application Deadline: July 5, 2022
Read More

Cancer Control Research in Persistent Poverty Areas (U54)
Through this FOA, the NCI invites applications for Cancer Control Research in Persistent Poverty Areas (Persistent Poverty Initiative). The goal is to provide resources to support the time and effort of transdisciplinary teams, in collaboration with institutions, clinics, and communities/tribes, to develop a cancer prevention and control research program and provide support to early-career investigators that focuses on and serves populations living in persistent poverty areas.
Application Deadline: July 6, 2022
Read More

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)
The purpose of this FOA is to invite applications for TCORS to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the Research Objectives related to the regulatory authority of the FDA Center for Tobacco Products.
Application Deadline: July 14, 2022
Read More

SBIR Phase IIIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44)
This FOA solicits SBIR applications from small business concerns that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency.
Application Deadline: August 6, 2022
Read More

Small Business Transition Grant For Early Career Scientists (R42)
Through this FOA, the NCI, National Institute of Biomedical Imaging and Bioengineering (NIBIB), and National Institute on Drug Abuse (NIDA) intend to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses.
Application Deadline: August 22, 2022
Read More